These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 28803791)
1. Squamous Differentiation Predicts Poor Response to Cisplatin-Based Chemotherapy and Unfavorable Prognosis in Urothelial Carcinoma of the Urinary Bladder. Minato A; Fujimoto N; Kubo T Clin Genitourin Cancer; 2017 Dec; 15(6):e1063-e1067. PubMed ID: 28803791 [TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder. Minato A; Noguchi H; Tomisaki I; Fukuda A; Kubo T; Nakayama T; Fujimoto N Cancer Control; 2018; 25(1):1073274818800269. PubMed ID: 30213195 [TBL] [Abstract][Full Text] [Related]
3. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364 [TBL] [Abstract][Full Text] [Related]
4. The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer. Gordetsky JB; Montgomery KW; Giannico GA; Rais-Bahrami S; Thapa P; Boorjian S; Frank I; Cheville J Int J Surg Pathol; 2022 Feb; 30(1):6-14. PubMed ID: 34180731 [No Abstract] [Full Text] [Related]
5. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation. Khaled HM; Shafik HE; Zabhloul MS; Ghoneim M; Saber RA; Manie M; Enein HA; Megeed HA; Mansur O; Sherbini ME; Mahran TZ; Kalawee ME; Badran A; Ramadan SM Clin Genitourin Cancer; 2014 Oct; 12(5):e233-40. PubMed ID: 24889794 [TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. Zargar-Shoshtari K; Sverrisson EF; Sharma P; Gupta S; Poch MA; Pow-Sang JM; Spiess PE; Sexton WJ Clin Genitourin Cancer; 2016 Feb; 14(1):82-8. PubMed ID: 26411593 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155 [TBL] [Abstract][Full Text] [Related]
8. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy. Li Q; Assel M; Benfante NE; Pietzak EJ; Herr HW; Donat M; Cha EK; Donahue TF; Bochner BH; Dalbagni G Eur Urol Focus; 2019 Jan; 5(1):104-108. PubMed ID: 28753857 [TBL] [Abstract][Full Text] [Related]
9. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications]. Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875 [TBL] [Abstract][Full Text] [Related]
10. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease? Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973 [TBL] [Abstract][Full Text] [Related]
11. Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Mitra AP; Bartsch CC; Bartsch G; Miranda G; Skinner EC; Daneshmand S Urol Oncol; 2014 Feb; 32(2):117-27. PubMed ID: 23477878 [TBL] [Abstract][Full Text] [Related]
15. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). Scosyrev E; Ely BW; Messing EM; Speights VO; Grossman HB; Wood DP; de Vere White RW; Vogelzang NJ; Trump DL; Natale RB; Tangen CM; Crawford ED; Thompson IM BJU Int; 2011 Sep; 108(5):693-9. PubMed ID: 21105991 [TBL] [Abstract][Full Text] [Related]
16. USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer. Liew MS; Azad A; Tafreshi A; Eapen R; Bolton D; Davis ID; Sengupta S BJU Int; 2013 Nov; 112 Suppl 2():74-82. PubMed ID: 24127680 [TBL] [Abstract][Full Text] [Related]
17. A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy. Zargar-Shoshtari K; Zargar H; Lotan Y; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC J Urol; 2016 Jan; 195(1):53-9. PubMed ID: 26205531 [TBL] [Abstract][Full Text] [Related]